Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kairos PharmaKAPA +2.07%15 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates KAPA with a GF Score™ of 15/100. Among 967 Biotechnology companies, Kairos Pharma ranks worse than 103412.51% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kairos Pharma's Debt-to-Equity or its related term are showing as below:
During the past 6 years, the highest Debt-to-Equity Ratio of Kairos Pharma was 0.04. The lowest was -0.49. And the median was -0.33.
KAPA's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kairos Pharma Debt-to-Equity Related Terms
Kairos Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kairos Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAPA vs ACXP, PULM, ADIL: Debt-to-Equity Comparison
For the Biotechnology subindustry, Kairos Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kairos Pharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kairos Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kairos Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kairos Pharma (KAPA) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kairos Pharma and its competitors. According to the industry distribution chart, Kairos Pharma ranks #999999 out of 967 companies in the Biotechnology industry.
Is Kairos Pharma's Debt-to-Equity too high?
Kairos Pharma's current Debt-to-Equity is 0.00. Based on the distribution chart, Kairos Pharma ranks #999999 out of 967 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's Debt-to-Equity compare to ACXP and PULM?
According to the Biotechnology industry distribution chart, Kairos Pharma ranks #999999 out of 967 companies for Debt-to-Equity. This places Kairos Pharma in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kairos Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kairos Pharma's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score
Get the complete analysis for KAPA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAPA has been successfully added to your 
